SCHEMBL4031035

SCHEMBL4031035

CCOC(CCO)c1ccc(OCc2nc(-c3cccs3)oc2C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.65
PPARG P37231 8/20 0.54
KDM4E B2RXH2 8/20 0.43
PPARD Q03181 3/20 0.43
ALDH1A1 P00352 6/20 0.43
MAPT P10636 4/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4029821 0.91 PPARA (0.65) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4025632 0.91 PPARA (0.61) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4025495 0.91 PPARA (0.60) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4025238 0.88 PPARA (0.69) PPARAPPARGPPARD
SCHEMBL4027986 0.85 PPARG (0.64) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4029070 0.84 PPARA (0.63) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4026911 0.84 FFAR1 (0.56) PPARAPPARGMAPT
SCHEMBL4031030 0.82 PPARA (0.74) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4031028 0.82 PPARA (0.69) PPARAPPARGKDM4EPPARDALDH1A1
SCHEMBL4744872 0.81 PPARA (0.64) PPARAPPARGKDM4EPPARDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP claimed
US-20060142277-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED 2006-06-29 US claimed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed
US-20060142277-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142277-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 PPARA 2339/4885PPARG 2043/4885KDM4E 4614/4885
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 PPARA 2339/4885PPARG 2043/4885KDM4E 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.